GALNT2 effect on HDL-cholesterol and triglycerides levels in humans: Evidence of pleiotropy?

• Published in: Nutrition, metabolism, and cardiovascular diseases Vol. 27; no. 4; pp. 281 - 282
• Main Authors: Di Paola, R, Marucci, A, Trischitta, V
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2017
• Subjects: Animals; Biomarkers - blood; Cardiovascular; Cholesterol, HDL - blood; Dyslipidemias - blood; Dyslipidemias - enzymology; Dyslipidemias - epidemiology; Dyslipidemias - genetics; Expression levels; GALNT2; Gene Expression Regulation, Enzymologic; Genetic Pleiotropy; Genetic Predisposition to Disease; Genotype; Humans; Lipid levels; N-Acetylgalactosaminyltransferases - genetics; N-Acetylgalactosaminyltransferases - metabolism; Polypeptide N-acetylgalactosaminyltransferase; Triglycerides - blood; GALNT2; Lipid levels; Expression levels
• ISSN: 0939-4753; 1590-3729
• DOI: 10.1016/j.numecd.2016.11.006

Abstract A wide range of studies both in humans and animal models point GALNT2 as a shaper of serum HDL-C and TG levels. Available data in humans indicate that, while under conditions of extreme GALNT2 loss-of-function HDL-C is the main target, a fine-tuning of GALNT2 changes is mostly associated with TG levels. Understanding whether different degrees of GALNT2 change do modulate different serum lipid fractions and, if so, addressing the mechanisms underlying such pleiotropic effects has the potential not only to improve our understanding of HDL-C and TG metabolism, but also to make GALNT2 becoming a target for treating atherogenic dyslipidemia and related clinical events.